The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01E | Protein kinase inhibitors | |
4
|
L01EP | Cellular-mesenchymal-epithelial transition factor (c-MET) kinase inhibitors |
| Code | Title | |
|---|---|---|
| L01EP01 | ||
| L01EP02 | ||
| L01EP03 |
| Active Ingredient |
|---|
|
Capmatinib is an inhibitor of the MET receptor tyrosine kinase. Capmatinib inhibits MET phosphorylation (both autophosphorylation and phosphorylation triggered by the ligand hepatocyte growth factor [HGF]), MET-mediated phosphorylation of downstream signalling proteins, as well as proliferation and survival of MET-dependent cancer cells. |
|
Tepotinib is a reversible Type I adenosine triphosphate (ATP)-competitive small molecule inhibitor of MET. Tepotinib blocked MET phosphorylation and MET-dependent downstream signalling in a dose-dependent manner. Tepotinib demonstrated pronounced anti-tumour activity in tumours with oncogenic activation of MET, such as METex14 skipping alterations. |
| Document | Type | Information Source | |
|---|---|---|---|
| TABRECTA Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| TABRECTA Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| TEPMETKO Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| TEPMETKO Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) |